Zuccon Gianmarco, D'Oria Mario, Gonçalves Frederico Bastos, Fernandez-Prendes Carlota, Mani Kevin, Caldeira Daniel, Koelemay Mark, Bissacco Daniele, Trimarchi Santi, Van Herzeele Isabelle, Wanhainen Anders
Vascular Division, Cardiovascular Department, HPG23 Hospital, Bergamo, Italy. Electronic address: http://www.twitter.com/MarioDoria14.
Division of Vascular and Endovascular Surgery, Cardiovascular Department, University Hospital of Trieste ASUGI, Trieste, Italy.
Eur J Vasc Endovasc Surg. 2023 Sep;66(3):352-361. doi: 10.1016/j.ejvs.2023.06.017. Epub 2023 Jun 24.
The primary objectives of this scoping review were to assess the rate of and risk factors for type Ib endoleak and to evaluate the extent of the evidence base that links type Ib endoleak to short and long term outcomes in patients undergoing endovascular aneurysm repair (EVAR) for abdominal aortic aneurysm (AAA).
Potentially eligible studies were searched in the Cochrane Central Register of Controlled Trials, MEDLINE, Web of Science Core Collection, SciELO Citation Index, Russian Science Citation Index, and KCI-Korean Journal Database. A scoping review was performed according to PRISMA extension for Scoping Reviews.
A total of 27 articles (four prospective registries and 23 retrospective cohort studies) dealing with type Ib endoleak were included in the final analysis. The number of patients reported on was 7 197, with follow up ranging between 12 months and 93 months. The reported frequency of type Ib endoleak in patients treated with EVAR ranged from 0% to 8%, Patient and or procedure related factors associated with risk of type Ib endoleak were (1) common iliac artery (CIA) diameter ˃ 18 mm requiring use of flared stent graft limbs (FLs) ˃ 20 mm, (2) length of CIA landing zone ˂ 20 mm, (3) marked iliac tortuosity, and (4) large initial AAA diameter. Depending on the study, 50 - 100% of type Ib endoleaks were corrected by endovascular means, with a reported immediate technical success of 100% in the studies providing this information.
Type Ib endoleak after EVAR has been reported to occur in 0 - 8% of cases. Several anatomical features, including CIA diameter ˃ 18 mm or requiring the use of FLs ˃ 20 mm, length of CIA landing zone ˂ 20 mm, marked iliac tortuosity, and large initial AAA diameter, could increase the risk of type Ib endoleak and may require alternative therapeutic options and or more stringent follow up. Therefore, this updated scoping review provides a comprehensive summary of the frequency, risk factors, prognosis, and treatment of type Ib endoleaks, and has identified knowledge gaps in the literature to guide further studies.
本范围综述的主要目的是评估Ib型内漏的发生率和危险因素,并评估将Ib型内漏与接受腹主动脉瘤(AAA)血管内动脉瘤修复术(EVAR)患者的短期和长期结局相关联的证据基础的范围。
在Cochrane对照试验中央注册库、MEDLINE、科学网核心合集、SciELO引文索引、俄罗斯科学引文索引和KCI-韩国期刊数据库中检索潜在符合条件的研究。根据PRISMA范围综述扩展版进行范围综述。
最终分析纳入了27篇涉及Ib型内漏的文章(4篇前瞻性注册研究和23篇回顾性队列研究)。报告的患者数量为7197例,随访时间为12个月至93个月。接受EVAR治疗的患者中报告的Ib型内漏发生率为0%至8%。与Ib型内漏风险相关的患者和/或手术相关因素包括:(1) 髂总动脉(CIA)直径>18mm,需要使用直径>20mm的喇叭状支架移植物肢体(FLs);(2) CIA着陆区长度<20mm;(3) 明显的髂动脉迂曲;(4) 初始AAA直径较大。根据研究,50%-100%的Ib型内漏通过血管内方法得到纠正,在提供此信息的研究中,报告的即时技术成功率为100%。
据报道,EVAR术后Ib型内漏的发生率为0%-8%。包括CIA直径>18mm或需要使用直径>20mm的FLs、CIA着陆区长度<20mm、明显的髂动脉迂曲和初始AAA直径较大在内的几个解剖学特征,可能会增加Ib型内漏的风险,可能需要替代治疗方案和/或更严格的随访。因此,本次更新的范围综述全面总结了Ib型内漏的发生率、危险因素、预后和治疗情况,并确定了文献中的知识空白,以指导进一步的研究。